Abstracts tagged "interleukins (IL) and mouse model"

Abstract Number: 332 • 2014 ACR/ARHP Annual Meeting
Improvement of the Stability of RNA Aptamers Against Interleukin-17A
Natsuki Otaki¹, Asako Sasaki¹, Shinsuke Hiramoto¹, Masakazu Nagamine¹, Shigeyuki Mori¹, Tomoyoshi Kayo¹, Kuniyoshi Hota¹, Masayuki Takahashi¹, Kazuhiko Haruta² and Yoshikazu Nakamura^3,4, ¹Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ²2-33-7 Oizumi, Nerima, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ³Division of RNA Medical Science, The Institute of Medical Science, The University Of Tokyo, Tokyo, Japan, ⁴RIBOMIC Inc., Tokyo, Japan
Background/Purpose Aptamers are RNA or DNA oligonucleotides selected for their capacity to specifically bind and inhibit the function of a target protein. The effect is…
Abstract Number: 2820 • 2013 ACR/ARHP Annual Meeting
Disease-Regulated Local Interleukin-10 Gene Therapy Diminishes Synovitis and Articular Cartilage Damage In Experimental Arthritis
Eline A. Vermeij¹, Mathijs G.A. Broeren¹, Miranda B. Bennink¹, Onno J. Arntz², Inger Gjertsson³, Wim B. van den Berg¹ and Fons A.J. van de Loo¹, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a chronic destructive autoimmune disease and in most patients the disease follows an intermittent course with periods of exacerbation and…
Abstract Number: 2713 • 2013 ACR/ARHP Annual Meeting
IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice
Yanna Ding¹, Hui-Chen Hsu^2,3, Jun Li⁴, PingAr Yang⁴, Qi Wu⁴, Allan J. Zajac⁵ and John D. Mountz^3,6, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Birmingham VA Medical Center, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Follicular T helper (Tfh) cells have been correlated with germinal center (GC) formation, autoantibody production and disease severity in human systemic lupus erythematosus (SLE).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].